MarginsXMarginsX
Home › Markets › Health Care › SNTI

Senti Biosciences Holdings Inc. (SNTI)

SNTI trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.1360
-2.86% on the day
Market cap
$5.2M
Nano cap
Revenue · 2025
$22K
Prior year not contiguous
Net income · 2025
-$61.4M
-279263.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1854270/000162828026021580/0001628280-26-021580-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerSNTI on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2021
SEC CIK0001854270

Financials · 2025

LineValue
Revenue$22K
Net income-$61.4M
Operating income-$68.8M
Net margin-279263.6%
Operating margin-312631.8%
Revenue growthNo prior-year revenue to compare
Cash$16.4M
Total assets$51.2M
P/E (computed)Net income was not positive
P/S (computed)237.7×

Warning signs

Cash runway
2.0 months
$6.5M cash at June 30, 2026
Share count, 1 year
+19.1%
2025-07-31 to 2026-07-31 · +599.2% over 3 years
Going-concern doubt
Yes
10-Q filed August 14, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"Notes to Condensed Consolidated Financial Statements (Continued) (Unaudited) the Company's liquidity, the Company concluded that substantial doubt continued to exist and that the Company's cash and cash equivalents of $ 6.5 million as of June 30, 2026, were not sufficient for the Company to continue as a going concern for at least one year from the issuance date of these condensed consolidated financial statements."
10-Q 2026-08-14
Cash and burn$6.5M cash; operating cash flow -$9.5M a quarter.Report 2026-06-30
Shares outstanding31,144,754 (2026-07-31); 26,160,206 a year earlier; 44,545,186 three years earlier. 3y figure adjusted for split (1-for-10 overall).Cover page 2026-07-31
Reverse splits, 3 years1; latest 1-for-10 on 2024-07-18Source 2024-07-18
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedownsLatest 2026-05-01
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2026-09-02
AuditorKPMG LLP, San Francisco, California, United StatesPCAOB Form AP 2026-04-21
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
$17K-$12.8M-$14.2M$6.5M$4.0MNeeds four quarters10-Q 2026-08-14
Q1 2026
2026-03-31
$16K-$4.2M-$7.5M$8.9MNo debt tagsNeeds four quarters10-Q 2026-05-14
Q4 2025
2025-12-31
Not filed-$14.5M-$6.9M$16.4M$0$22K10-K 2026-03-27
Q3 2025
2025-09-30
Not filed-$18.1M-$9.4M$12.2MNo debt tagsNeeds four quarters10-Q 2025-11-13
Q2 2025
2025-06-30
$0-$14.7M-$13.1M$21.6MNo debt tags$010-Q 2026-08-14
Q1 2025
2025-03-31
$0-$14.1M-$14.1M$33.8MNo debt tags$010-Q 2026-05-14
Q4 2024
2024-12-31
$0-$610K-$13.5M$48.3MNo debt tags$010-K 2025-03-20
Q3 2024
2024-09-30
$0-$28.9M-$7.9M$10.5MNo debt tags$010-Q 2024-11-14

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.

Price moves

WindowReturn
1 week-12.5%
1 month-45.1%
3 months-63.5%
Year to date-86.5%
1 year-92.2%
From 52-week high-94.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
AIMAIM ImmunoTech Inc.$0.1310-8.77%$5.2M
BTTCBlack Titan Corporation$0.2873-9.20%$4.3M
CRISCuris Inc.$0.4358-2.07%$4.1M
LIMNLiminatus Pharma Inc.$2.97-0.67%$4.0M
CELZCreative Medical Technology Holdings Inc.$0.5201-1.51%$4.0M
INABIN8bio Inc.$0.8160-0.49%$8.8M
TCRXTScan Therapeutics Inc.$0.1451-9.65%$9.2M
INTSIntensity Therapeutics Inc.$3.07-0.32%$10.1M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier